GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 376.19% from the stock’s current price.

Separately, Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

GH Research Stock Performance

GH Research stock traded down $0.58 during trading on Friday, hitting $8.40. The company’s stock had a trading volume of 82,044 shares, compared to its average volume of 128,287. The stock’s fifty day moving average is $8.43 and its 200 day moving average is $9.23. GH Research has a 1-year low of $5.50 and a 1-year high of $14.99. The stock has a market capitalization of $437.04 million, a price-to-earnings ratio of -10.63 and a beta of 0.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its stake in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).